Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA EBITDA Margin

EBITDA as a percentage of revenue.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -325.3%

EBITDA Margin was -325.3% in Q1 FY2026, down 183.8 pp from a year earlier. On a trailing-twelve-month basis it was -149.2%, up 14.0 pp year over year. Over 3 fiscal years it widened by 281.5 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -215.4% for the fiscal year ending Dec 2026, down from -149.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-325.3%-220.8 pp QoQ
Last fiscal yearDec 2025
-149.6%+63.7 pp YoY
LTMMar 2026
-149.2%+14.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-183.8 pp-94.0 pp+89.9 pp
1 year+63.7 pp-65.8 pp-129.5 pp
3 years+281.5 pp-4.1 pp-285.6 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-149.6%
Year-over-year change
+63.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How DNA compares with its peers on the latest reported figures

  • DNA's LTM Mar 2026 EBITDA Margin of -149.2% is the 5th highest of the 7 companies compared; the peer median is -88.8%.
  • Its year-over-year change of +14.0 pp is the 5th highest of 7, against a peer median of +91.5 pp.
  • Over three fiscal years its change of +281.5 pp compares with a peer median of +0.1 pp.
DNA Competitors Peer median
EBITDA Margin for DNA and competitors
Company Period LTM level YoY 3-year change
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-26.6% +89.9 pp-148.5 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-48.8% +93.1 pp—
VALNValneva SELTM Mar 2026-57.7% -35.6 pp+0.1 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-120.0% +290.8 pp+619.2 pp
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-149.2% +14.0 pp+281.5 pp
ARVNArvinas, Inc.LTM Mar 2026-242.2% -232.7 pp+164.2 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
REPLReplimune Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding DNA) -88.8%+91.5 pp+0.1 pp

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.